EP3169692A1 - Nouvelle forme de sofosbuvir et sa méthode de préparation - Google Patents

Nouvelle forme de sofosbuvir et sa méthode de préparation

Info

Publication number
EP3169692A1
EP3169692A1 EP15747360.4A EP15747360A EP3169692A1 EP 3169692 A1 EP3169692 A1 EP 3169692A1 EP 15747360 A EP15747360 A EP 15747360A EP 3169692 A1 EP3169692 A1 EP 3169692A1
Authority
EP
European Patent Office
Prior art keywords
sofosbuvir
accordance
solvent
crystalline form
ester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP15747360.4A
Other languages
German (de)
English (en)
Inventor
Martin STEFKO
Ondrej Dammer
Lukas KREJCIK
Stanislav MAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zentiva KS
Original Assignee
Zentiva KS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentiva KS filed Critical Zentiva KS
Publication of EP3169692A1 publication Critical patent/EP3169692A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives

Definitions

  • the invention relates to a new crystalline form of SOFOSBUVIR of formula (I), chemically isopropyl ((S)-(((2R 5 3R,4R i 5R)-5-(2,4-dioxo-3 ,4-dihydropyrimidin-l (2H)-yl)-4-fluoro-3- hydroxy-4-metiLyltetrahydrofur ⁇ and a method for the preparation thereof.
  • Sofosbuvir is a compound designed for treatment of hepatitis C infection.
  • the compound was first described in the patent application WO2008121634; a general preparation procedure of this compound and a number of other compounds with a similar composition are included in the above mentioned application on pages 668 to 671.
  • the synthesis is further documented in examples 13 to 66. Reproduction of these procedures provided sofosbuvir in an amorphous form (foam or oil form).
  • SOFOSBUVIR is a so-called prodrug, which is easily enzymatically transformed directly in the liver to the active substance 2'-deoxy-2'-a-fiuoro- -C-metbyluridine-5'-triphosphate, which serves as an RNA polymerase inhibitor (NS5B protein), inhibiting the synthesis of viral RNA.
  • Sofosbuvir represents the first non-interferon treatment of chronic hepatitis C with the cure rate of up to 90%.
  • the patent application WO2010/135569 describes preparation and characterization of five polymorphs and an amorphous form of Sofosbuvir, while the application WO2011/123645 adds form VI to this list.
  • Form VI is prepared by crystallization from an aqueous solution, but it is surprisingly non-hygroscopic and stable when exposed to the air.
  • Forms V and IV are prepared by crystallization from anisole and acetonitrile. However, both of them pass to Form I by mere filtration.
  • Form III is described as a 1 :1 solvate with chloroform, while form II is a 1:1 solvate with dichloromethane.
  • Form I represents a non- solvated form of Sofosbuvir.
  • the patent further describes single crystal X-ray crystallographic data of Forms I, II, III.
  • the invention provides a new polymorphic form of Sofosbuvir Z-l, its preparation and characterization.
  • the prepared polymorphic form exhibits a high physical stability, which makes it a suitable candidate for use in a pharmaceutical composition.
  • Fig. 1 IR spectrum of Sofosbuvir, Form Z-l .
  • Fig.2 RAMAN spectrum of Sofosbuvir, Form Z-l .
  • Fig. 3 Solid phase 13 C ssNMR of SOFOSBUVIR, Form Z-l .
  • Fig. 4 Solid phase 19 F ssNMR of Sofosbuvir Form Z-l.
  • Fig. 5 X-ray powder pattern of Sofosbuvir Form Z-l .
  • Fig. 6 DVS curve of Sofosbuvir Form Z-l .
  • the invention provides a new polymorphic form of Sofosbuvir, referred to as Z-l, which has not been described in literature yet.
  • the main advantage of this new polymorphic form consists in its better purification abilities as compared to the existing described form 1 (WO2011/123645).
  • This form is anhydrous, non-hygroscopic and appears to be chemically and polymorphously stable.
  • Form Z-l has been characterized with the use of the following analytic methods: X-Ray powder diffraction (XRPD), Raman spectroscopy, IR spectroscopy, NMR spectroscopy and dynamic vapour sorption (DVS).
  • Sofosbuvir (I) obtained in accordance with the patent O2011/123645 (FORM I) exhibits max. 98.0% purity (according to HPLC). Crystallization from a mixture of DCM/toluene according to the said patent application, as well as repeated crystallization for this mixture, does not virtually lead to any further purification. It is obvious that repeated crystallization does not lead to a reduction of the contents of impurities below the defined limits (0.10 and 0.15%). Such raw material is then not suitable for pharmaceutical production.
  • Form Z-l of Sofosbuvir in accordance with this invention is characterized by the following reflections in an X-ray powder pattern: 8.0; 12.3; 17.1; 19.9 and 20.8 ⁇ 0.2° 2-theta with the use of CuKa radiation. Still, more diffraction peaks can be found in the X-ray powder pattern: 10.3; 13.4; 16.1; 17.9; 19.3; 23.6; 24.8 and 27.0 ⁇ 0.2° 2-theta.
  • Table 1 An X-ray powder pattern of this polymorphic form is shown in Figure 5.
  • Form Z-l of Sofosbuvir in accordance with this invention is characterized by the following reflection bands in the FTIR spectrum: 3251, 1719, 1669, 1265, 1092 and 945 + 4 cm “1 (Fig. 1).
  • Form Z-l of Sofosbuvir in accordance with this invention is characterized by the following maximum intensity bands in the FT-Raman spectrum: 2987, 1718, 1671, 1373, 1217, 1007, 774 ⁇ 4 cn 1 (Fig. 2).
  • Form Z-l of Sofosbuvir in accordance with this invention is further characterized with solid phase 13 C and 19 F ssNMR.
  • a solid phase 13 C ssNMR spectrum of this polymorphic form is shown in Figure 3.
  • a solid phase 19 F ssNMR spectrum of this polymorphic form is shown in Figure 4.
  • the dynamic vapour sorption record indicates stability of the polymorph in the range of 0 to 70% of relative humidity, where the water content increase in the sample has been in the range of 0 to 0.4%.
  • the relative humidity interval of 70-90% a significant increase of water sorption from 0.4 to 6.4% has been registered.
  • a subsequent reversal of the cycle (desorption) and reduction of relative humidity from 90% does not change the water content, which remains to be 6.4%.
  • 60% relative humidity is achieved, abrupt desorption of water occurs, the water content dropping to 0.4% at 50% relative humidity, while the water content further slowly decreases down to 0% at 0% relative humidity.
  • a subsequently repeated sorption/desorption process follows the above mentioned course.
  • Form Z-l is stable and resistant to humidity when exposed to the air.
  • the invention also includes a method for the preparation of the new Form Z-l.
  • Form Z-l can be obtained by crystallization of Sofosbuvir from an ester of a C3 to C5 alcohol and CI to C4 acids.
  • the ester is preferably selected such that the total number of carbon atoms be 5 to 8.
  • Propyl ester of butanoic acid or pentyl ester of formic acid thus appear to be convenient.
  • the ester may be composed of primary, secondary or tertiary alcohols.
  • the carbon skeleton of the acid may be linear or branched.
  • esters may be used either pure or in a mixture with another solvent, a so-called co-solvent. Less polar solvents are selected as the co-solvents.
  • co-solvents For example, C6 to C9 aromatics, or C6 to C9 alicyclic hydrocarbons, or CI to C4 chlorinated hydrocarbons, substituted with one or more chlorine atoms have proved to be suitable.
  • An example may be cyclohexane, toluene or DCM.
  • the new polymorphic Form Z-1 of Sofosbuvir exhibits 99.8% purity after the first crystallization from a mixture of n-butyl acetate/toluene already; the subsequent re- crystallization provides a product with 99.9% purity, while all the detected impurities are below the defined limit values (0.10 and 0.15%).
  • the quality of the API prepared this way meets the requirements for pharmaceutical use.
  • n-butyl acetate as the solvent in the preparation process of this new polymorphic Form Z-1 of Sofosbuvir.
  • This solvent is non-toxic with the limit of 5000 ppm for the final API, involatile (boiling temperature 126°C) and it does not produce explosive vapour. This makes it a suitable solvent for possible industrial production of Sofosbuvir.
  • the measurement was carried out with a flat powder sample applied onto a Si plate.
  • a 10mm mask and a 1/4° fixed anti- dispersion slit were used.
  • the irradiated area of the sample was 10 mm, programmable divergence slits were used.
  • For the correction of the secondary array 0.02 rad Soller slits and a 5.0 anti-dispersion slit were used.
  • the ATR(ZnSe)-FTIR spectra were measured using a FTIR Nicolet Nexus spectrometer (Thermo, USA). 12 scans with the resolution of 4 cm "1 were applied to one spectrum.
  • FT-Raman spectra were measured using a RFS 100/S FTIR spectrometer (Bruker, Germany). 128 scans with the resolution of 4 cm “1 were applied to one spectrum. A laser device with the wavelength of 1064 nm and the output of 250 mW was used as the source of excitation radiation.
  • NMR spectra were measured with an Avance 500 device by Bruker. 1H spectra were measured at the frequency of 500.13 MHz, 13 C at the frequency of 125.8 MHz. The sample was measured in a deuterated solvent specified for the particular analysis, normally at 25°C (unless specified otherwise for a particular analysis). The chemical shift ⁇ is expressed in ppm units, interaction constants J in Hz. The spectra were normally referenced to the residual solvent content.
  • Solid state NMR spectra were measured using a Bruker Avance III 400 WB spectrometer.
  • I3 C CP MAS experiments were measured with a 4-mm probe with the rotation rate of 13 kHz, contact time 2 ms
  • the dynamic vapour sorption (DVS) patterns were measures with a DVS Advantage 1 device made by the company Surface Measurement Systems.
  • the sample charge in a quartz pot was 20.2 mg and the temperature in the device was 25.4°C.

Abstract

L'invention concerne la forme cristalline Z-1 de sofosbuvir, caractérisée par les pics de diffraction suivants: 8,0; 12,3; 17,1; 19,9 et 20,8 ± 0,2° 2-thêta avec utilisation de rayonnement CuKα; et sa méthode de préparation.
EP15747360.4A 2014-07-17 2015-07-17 Nouvelle forme de sofosbuvir et sa méthode de préparation Withdrawn EP3169692A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CZ2014-502A CZ2014502A3 (cs) 2014-07-17 2014-07-17 Nová forma sofosbuviru a způsob její přípravy
PCT/CZ2015/000078 WO2016008461A1 (fr) 2014-07-17 2015-07-17 Nouvelle forme de sofosbuvir et sa méthode de préparation

Publications (1)

Publication Number Publication Date
EP3169692A1 true EP3169692A1 (fr) 2017-05-24

Family

ID=53783528

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15747360.4A Withdrawn EP3169692A1 (fr) 2014-07-17 2015-07-17 Nouvelle forme de sofosbuvir et sa méthode de préparation

Country Status (3)

Country Link
EP (1) EP3169692A1 (fr)
CZ (1) CZ2014502A3 (fr)
WO (1) WO2016008461A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2988393C (fr) 2014-06-13 2023-08-22 Ratiopharm Gmbh Formes solides de sofosbuvir
TW201609709A (zh) * 2014-08-01 2016-03-16 Ｈｃ製藥公司 呈晶形之索非布弗（Ｓｏｆｏｓｂｕｖｉｒ）及其製備方法
US10738071B2 (en) 2016-03-17 2020-08-11 Mylan Laboratories Limited Polymorphic forms of sofosbuvir
RU2656228C9 (ru) * 2017-06-13 2019-04-16 Олег Ростиславович Михайлов Слабозакристаллизованная β-модификация (S)-изопропил 2-((S)-(((2R,3R,4R,5R)-5-(2,4-диоксо-3,4-дигидропиримидин-(2Н)-ил)-4-фтор-3-гидрокси-4-метилтетрагидрофуран-2-ил)метокси)-(фенокси)фосфориламино)пропаноата, способ её получения и фармацевтическая композиция на её основе
EP3661944A1 (fr) 2017-08-03 2020-06-10 Sandoz AG Hydrate de sofosbuvir
CN109517018B (zh) * 2018-12-29 2021-05-04 石药集团中奇制药技术（石家庄）有限公司 一种索磷布韦新晶型及其制备方法
CN111072742B (zh) * 2019-12-23 2022-12-02 南京正大天晴制药有限公司 一种治疗丙肝药物的新晶型及其组合物
WO2021203409A1 (fr) * 2020-04-10 2021-10-14 南京正大天晴制药有限公司 Nouvelle forme cristalline non hygroscopique à faible variabilité pour le traitement de l'hépatite c

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
CN102858790A (zh) 2010-03-31 2013-01-02 吉利德制药有限责任公司 核苷氨基磷酸酯

Also Published As

Publication number Publication date
WO2016008461A1 (fr) 2016-01-21
CZ2014502A3 (cs) 2016-01-27

Similar Documents

Publication Publication Date Title
EP3169692A1 (fr) Nouvelle forme de sofosbuvir et sa méthode de préparation
KR101795096B1 (ko) 광학 활성 디아민 유도체의 염의 제조 방법
AU2018244451A1 (en) Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3) pyridazine-3-carboxamide
EP3386945A1 (fr) Formes solides d'ester éthylique d'acide (2r,4s)-5-(biphényl-4-yl)-4-[(3-carboxypropionyl)amino]-2-méthylpentanoïque, ses sels et son procédé de préparation
EP3218351B1 (fr) Procédé de préparation, d'isolation et de purification de formes pharmaceutiquement applicables de ahu-377
EP2885266A1 (fr) Procédé de préparation de (2z,5z)-5-(3-chloro-4-((r)-2,3-dihydroxypropoxy)benzylidene)-2-(propylimino)-3-!(o-tolyl)thiazolidin-4-one et intermédiaire utilisé dans ledit procédé
JP2020535193A (ja) 結晶のリナグリプチン中間体およびリナグリプチンの調製のためのプロセス
CA2920080A1 (fr) Procede de preparation de rifaximine .kappa.
JP6692408B2 (ja) アピキサバンの二量体不純物およびその除去方法
JP2017518259A (ja) アピキサバンの合成の重要な中間体及び不純物：アピキサバングリコールエステル
JP2014516065A (ja) ７−クロロ−４−（ピペラジン−１−イル）−キノリンの新規合成方法
JP2020535192A (ja) レナリドミドの結晶形
EP2307354A1 (fr) Procédé de préparation d un dérivé de benzoylbenzène acétamide
CN110669027B (zh) 化合物和其酯、其制备方法和用途
KR100911720B1 (ko) 결정형 염산 사포그릴레이트의 제조방법
AU2018201013B2 (en) Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride
EP3277667A1 (fr) Procédé amélioré pour préparer de l'idélalisib
WO2015067230A1 (fr) Procédé de production et nouvelle forme cristalline d'un intermédiaire pour la synthèse du ticagrelor
CN111777521A (zh) 多构型长链苯基氨基酸类化合物的合成方法
KR101392993B1 (ko) 키랄 1,4-티아제핀 페닐부타노에이트 화합물의 제조방법
CN114478536A (zh) 四氢吡嗪稠环衍生物的制备方法
WO2016142173A1 (fr) Forme solide de 4-(2-méthyl-1h-imidazol-1-yl)-2,2-diphénylbutanenitrile
JP2014185091A (ja) ３−アミン−４−ピペリドン誘導体の製造方法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20170112

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20170907